A Phase 2a Study Assessing the Efficacy and Safety of STN1010905 Ophthalmic Suspension in Subjects with MGD

JRCT ID: jRCT2031210371

Registered date:08/10/2021

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: MGD (Meibomian Gland Dysfunction)
• Date of first enrollment: 18/10/2021
• Target sample size: 36
• Study type: Interventional

Intervention(s)

Screening period : Artificial tear (BID, Both eyes)
Treatment period : STN1010905 ophthalmic suspension or Placebo (BID, Both eyes)

Outcome(s)

• Primary Outcome: Sign of Meibomian glands

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

Outpatient
Diagnosed as MGD
Having ocular symptoms

Exclude criteria

Ocular disease which needs treatment expect MGD and DRYEYE
Requires contact lenses wear during the study
Any decision by the Investigator to terminate a subject in screening

Related Information

• Primary Sponsor: Migita Yukie